Author: Ewa Orlewska
View More View Less
  • 1 Centre for Pharmacoeconomics Warsaw Poland
  • 2 Corvinus University of Budapest Health Economics and Technology Assessment Research Centre Budapest Hungary
Restricted access

The healthcare reform package submitted to the Polish parliament could lead to a radical and fundamental change in existing business models and in the rules on marketing activities. The most important provisions introduced by the new Reimbursement Act are: fixed markups and prices of reimbursed medicines, introduction of a pay-back system, risk-sharing mechanisms, tax on income from reimbursements, a maximum (total) reimbursement budget, new therapeutic and economic criteria for various levels of reimbursement. Undoubtedly the planned changes will improve the functioning of the reimbursement procedure by increasing the transparency of the process. Challenges facing health policy in Poland are not unique: similar have been identified in Hungary. Owing to the similarities between both countries in healthcare systems, clinical practice patterns and economic indicators, it seems to be reasonable to develop partnerships in creating relevant regional databases and registries, and in examination of the generalisability and transferability of health technology assessment findings.

  • Boncz, I. — Brodszky, V. — Péntek, M. — Ágoston, I. — Nagy, Z. — Kárpáti, K. — Kriszbacher, I. — Fuszek, P. — Gulácsi, L. (2009): The Disease Burden of Colorectal Cancer in Hungary. European Journal of Health Economics 10(1): S35–S40.

    Gulácsi L. , 'The Disease Burden of Colorectal Cancer in Hungary ' (2009 ) 10 European Journal of Health Economics : S35 -S40.

    • Search Google Scholar
  • Brodszky, V. — Péntek, M. — Gulácsi, L. (2008a): Efficacy of Adalimumab, Etanercept and Infliximab Based on ACR50 Response in Psoriatic Arthritis after 24 Weeks Treatment. Scandinavian Journal of Rheumatology 37: 399–400.

    Gulácsi L. , 'Efficacy of Adalimumab, Etanercept and Infliximab Based on ACR50 Response in Psoriatic Arthritis after 24 Weeks Treatment ' (2008 ) 37 Scandinavian Journal of Rheumatology : 399 -400.

    • Search Google Scholar
  • Brodszky, V. — Nagy, V. — Farsang, C. — Kárpáti, K. — Gulácsi, L. (2008b): The Efficacy of Indapamide in Different Cardiovascular Outcomes; Meta-analysis. Orvosi Hetilap (Hungarian Medical Journal) 2(2): 181–191.

    Gulácsi L. , 'The Efficacy of Indapamide in Different Cardiovascular Outcomes; Meta-analysis ' (2008 ) 2 Orvosi Hetilap (Hungarian Medical Journal) : 181 -191.

    • Search Google Scholar
  • Brodszky, V. — Orlewska, E. — Péntek M. — Kárpáti, K. — Skoupá, J. — Gulácsi, L. (2010a): Challenges in Economic Evaluation of New Drugs: Experience with Rituximab in Hungary. Medical Science Monitor 16(1): SR1–5.

    Gulácsi L. , 'Challenges in Economic Evaluation of New Drugs: Experience with Rituximab in Hungary ' (2010 ) 16 Medical Science Monitor : SR1 -5.

    • Search Google Scholar
  • Brodszky, V. — Bálint, P. — Géher, P. — Hodinka, L. — Horváth, G. — Koó, É. — Péntek, M. — Polgár, A. — Seszták, M. — Szántó, S. — Ujfalussy, I. — Gulácsi, L. (2009): Disease Burden of Psoriatic Arthritis Compared to Rheumatoid Arthritis, Hungarian Experiment. Rheumatology International 30(2): 199–205.

    Gulácsi L. , 'Disease Burden of Psoriatic Arthritis Compared to Rheumatoid Arthritis, Hungarian Experiment ' (2009 ) 30 Rheumatology International : 199 -205.

    • Search Google Scholar
  • Brodszky, V. — Péntek, M. — Bálint, P. V. — Géher, P. — Hajdú, O. — Hodinka, L. — Horváth, G. — Koó, E. — Polgár, A. — Seszták, M. — Szántó, S. — Ujfalussy, I. — Gulácsi, L. (2010b): Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire, the Functional Status (HAQ) and the Utility (EQ-5D) Measures in Psoriatic Arthritis; Results from a Cross-sectional Survey. Scandinavian Journal of Rheumatology 39(4): 303–309.

    Gulácsi L. , 'Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire, the Functional Status (HAQ) and the Utility (EQ-5D) Measures in Psoriatic Arthritis; Results from a Cross-sectional Survey ' (2010 ) 39 Scandinavian Journal of Rheumatology : 303 -309.

    • Search Google Scholar
  • Draft of Reimbursement Act (2010): Draft Act on the Reimbursement of Drugs, Food Products for Special Dietary Purposes and Medical Devices with Public Funds, submitted for public consultations on 9 September 2010. http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/proj_ustawyref_09092010.pdf

  • Érsek, K. — Kovács, T. — Wimo, A. — Kárpáti, K. — Brodszky, V. — Péntek, M. — Jönsson, L. — Gustavsson, A. — McDaid, D. — Kenigsberg, P. A. — Valtonen, H. — Gulácsi, L. (2010): Costs of Dementia in Hungary, Journal of Nutrition, Health and Aging 14(8): 633–639.

    Gulácsi L. , 'Costs of Dementia in Hungary ' (2010 ) 14 Journal of Nutrition, Health and Aging : 633 -639.

    • Search Google Scholar
  • Gulácsi, L. (2007): The Time for Cost-effectiveness in the New European Union Member States: The Development and Role of Health Economics and Technology Assessment in the Mirror of the Hungarian Experience. European Journal of Health Economics 8(2): 83–88.

    Gulácsi L. , 'The Time for Cost-effectiveness in the New European Union Member States: The Development and Role of Health Economics and Technology Assessment in the Mirror of the Hungarian Experience ' (2007 ) 8 European Journal of Health Economics : 83 -88.

    • Search Google Scholar
  • Gulácsi, L. (2010): Future Challenges for Health Economics and Technology Assessment of Biological Drugs. European Journal of Health Economics 11(3): 235–238.

    Gulácsi L. , 'Future Challenges for Health Economics and Technology Assessment of Biological Drugs ' (2010 ) 11 European Journal of Health Economics : 235 -238.

    • Search Google Scholar
  • Gulácsi, L. — Boncz, I. — Drummond, M. (2004): Issues for Countries Considering Introducing the ‘fourth Hurdle’. The Case of Hungary. International Journal of Technology Assessment in Health Care 20(3): 337–341.

    Drummond M. , 'Issues for Countries Considering Introducing the ‘fourth Hurdle’. The Case of Hungary ' (2004 ) 20 International Journal of Technology Assessment in Health Care : 337 -341.

    • Search Google Scholar
  • Gulácsi, L. — Vas, G. — Pintér, I. — Kriszbacher, I. (2009b): Colorectal Cancer Screening Policy in Hungary. International Journal of Technology Assessment in Health Care 25(1): 109–110.

    Kriszbacher I. , 'Colorectal Cancer Screening Policy in Hungary ' (2009 ) 25 International Journal of Technology Assessment in Health Care : 109 -110.

    • Search Google Scholar
  • Gulácsi, L. — Brodszky, V. — Péntek, M. — Varga, S. — Vas, G. — Boncz, I. (2009a): History of Health Technology Assessment in Hungary. International Journal of Technology Assessment in Health Care 25Suppl 1: 120–126.

    Boncz I. , 'History of Health Technology Assessment in Hungary ' (2009 ) 25 International Journal of Technology Assessment in Health Care : 120 -126.

    • Search Google Scholar
  • GUS (2010): National Health Account 2008. Central Statistical Office. http://www.stat.gov.pl/cps/rde/xbcr/gus/PUBL_zos_narodowy_rachunek_zdrowia_2008.pdf

  • Health Barometer Report (2010): Polish Health care at bottom of pile. Warsaw Business Journal 6 Oct 2010. http://www.wbj.pl/article-51468-polish-health-care-at-bottom-of-pile.html?typ=ise

  • Makai, P. — Wagner, C. — Klazinga, N. — Boncz, I. — Gulácsi, L. (2008): Quality Management and Patient Safety; Survey Results from 102 Hungarian Hospitals. Health Policy 90(2–3) 175–180.

    Gulácsi L. , 'Quality Management and Patient Safety; Survey Results from 102 Hungarian Hospitals ' (2008 ) 90 Health Policy : 175 -180.

    • Search Google Scholar
  • Minier, T. — Péntek, M. — Brodszky, V. — Ecseki, A. — Kárpáti, K. — Polgár, A. — Czirják, L. — Gulácsi, L. (2009): Cost-of-illness of Patients with Systemic Sclerosis, Rheumatology 49(10): 1920–1928.

    Gulácsi L. , 'Cost-of-illness of Patients with Systemic Sclerosis ' (2009 ) 49 Rheumatology : 1920 -1928.

    • Search Google Scholar
  • Öesterle, A. — Gulácsi, L. (2007): Das Gesundheitssystem in Ungarn: Entwicklungen, Herausforderungen und Reformen, Soziale Sicherheit Sept. 418–429.

  • Öesterle, A. — Gulácsi, L. — Pechová, M. (2007): Gesundheitssytementwicklung in den MOE-Landern: Zwischen socialen Rechen and Marktallokation. Kurswechsel 2: 18–27.

    Pechová M. , 'Gesundheitssytementwicklung in den MOE-Landern: Zwischen socialen Rechen and Marktallokation ' (2007 ) 2 Kurswechsel : 18 -27.

    • Search Google Scholar
  • Orlewska, E. (2002): The Cost-effectiveness of Alternative Therapeutic Strategies for Management of Chronic Hepatitis B in Poland. Value in Health 5(5): 404–420.

    Orlewska E. , 'The Cost-effectiveness of Alternative Therapeutic Strategies for Management of Chronic Hepatitis B in Poland ' (2002 ) 5 Value in Health : 404 -420.

    • Search Google Scholar
  • Orlewska, E. — Gulácsi, L. (2009). Budget-impact Analyses: A Critical Review of Published Studies. PharmacoEconomics 27(10): 807–827.

    Gulácsi L. , 'Budget-impact Analyses: A Critical Review of Published Studies ' (2009 ) 27 PharmacoEconomics : 807 -827.

    • Search Google Scholar
  • Orlewska, E. — Mierzejewski, P. (2004): Polish Guidelines for Conducting Financial Analysis-proposal. Value in Health 7(1): 1–10.

    Mierzejewski P. , 'Polish Guidelines for Conducting Financial Analysis-proposal ' (2004 ) 7 Value in Health : 1 -10.

    • Search Google Scholar
  • Orlewska, E. — Budaj, A. — Tereszkowski-Kamimski, D. (2003): Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in acute coronary syndrome patients in Poland. Pharmacoeconomics 21(10): 737–748.

    Tereszkowski-Kamimski D. , 'Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in acute coronary syndrome patients in Poland ' (2003 ) 21 Pharmacoeconomics : 737 -748.

    • Search Google Scholar
  • Orlewska, E. — Zammit, D. — Yong, Yuan — Kutikova, L. — Berak, H. — Halota, W. — Hay, J. W. (2008): The Cost-effectiveness Analysis of Entecavir in the Treatment of Chronic Hepatitis B (CHB) in Poland. Experimental & Clinical Hepatology 4(3–4): 20–28.

    Hay J. W. , 'The Cost-effectiveness Analysis of Entecavir in the Treatment of Chronic Hepatitis B (CHB) in Poland ' (2008 ) 4 Experimental & Clinical Hepatology : 20 -28.

    • Search Google Scholar
  • Orlewska, E. — Mierzejewski, P - Zaborski, J. — Kruszewska, J. — Wicha, W. — Fryze, W. — Drozdowski, W. — Skibicka, I. — Mirowska-Guzel, D — Czlonkowski, A. — Czlonkowska, A. (2005): Cost of multiple sclerosis in Poland. European Journal of Neurology 12: 31–39.

    Czlonkowska A. , 'Cost of multiple sclerosis in Poland ' (2005 ) 12 European Journal of Neurology : 31 -39.

    • Search Google Scholar
  • Orlewska, E. — Ancuta, I. — Anic, B. — Codrenau, C. — Damjanov, N. — Djukic, P. — Ionescu, R. — Marinchev, L. — Nasonov, E. L. — Peets, T. — Praprotnik, S. — Rashkov, R. — Skoupa, J. — Tlustochowicz, W. — Tlustochowicz, M. — Tomsic, M. — Veldi, T. — Vojinovic, J. — Wiland, P. (2011): Access to Biologic Treatment in Rheumatoid Arthritis (RA) in Central and Eastern European (CEE) Countries. Medical Science Monitor 17(4): SR1–13.

    Wiland P. , 'Access to Biologic Treatment in Rheumatoid Arthritis (RA) in Central and Eastern European (CEE) Countries ' (2011 ) 17 Medical Science Monitor : SR1 -13.

    • Search Google Scholar
  • Péntek, M. — Brodszky, V. — Tóth, E. — Gulacsi, L. (2007a): Characteristics of Patients with Rheumatoid Arthritis in Hungary: Comparison with the QUEST-RA Study. Annals of Rheumatic Diseases 66: 1491–1496.

    Gulacsi L. , 'Characteristics of Patients with Rheumatoid Arthritis in Hungary: Comparison with the QUEST-RA Study ' (2007 ) 66 Annals of Rheumatic Diseases : 1491 -1496.

    • Search Google Scholar
  • Péntek, M. — Horváth, C. — Boncz, I. — Falusi, Z. — Tóth, E. — Sebestyén, E. — Majer, I. — Brodszky, V. — Gulácsi, L. (2008): Epidemiology of Osteoporosis Related Fractures in Hungary from the Nationwide Health Insurance Database, 1999–2003. Osteoporosis International 19: 243–249.

    Gulácsi L. , 'Epidemiology of Osteoporosis Related Fractures in Hungary from the Nationwide Health Insurance Database, 1999–2003 ' (2008 ) 19 Osteoporosis International : 243 -249.

    • Search Google Scholar
  • Péntek, M. — Kobelt, M. — Czirják, L. — Szekanecz, Z. — Poór, G. — Rojkovich, B. — Polgár, A. — Genti, G. — György Kiss, C. — Brodszky, V. — Májer, I. — Gulácsi, L. (2007b): Costs of Rheumatoid Arthritis in Hungary. Journal of Rheumatology 34:1437–1439.

    Gulácsi L. , 'Costs of Rheumatoid Arthritis in Hungary ' (2007 ) 34 Journal of Rheumatology : 1437 -1439.

    • Search Google Scholar
  • Poland Pharmaceuticals and Healthcare Report (2010): Poland Pharmaceuticals and Healthcare Report Q1 2011. Business Monitor International, http://www.companiesandmarkets.com/Market-Report/poland-pharmaceuticals-and-healthcare-report-q1-2011-405108.asp

  • Pricing Law (2001): Pricing Law of 5th July 2001. Journal of Acts 97/2001.

  • Redekop, K. — Orlewska, E. — Maciejewski, P. — Rutten, F. — Niessen, L. (2008): Cost and Effects of Secondary Prevention with Peridnopril in Stable Coronary Heart Disease in Poland. An Analysis of the Europa Study Including 1251 PolisPh atients. Pharmacoeconomics 26(10): 861–877.

    Niessen L. , 'Cost and Effects of Secondary Prevention with Peridnopril in Stable Coronary Heart Disease in Poland. An Analysis of the Europa Study Including 1251 PolisPh atients ' (2008 ) 26 Pharmacoeconomics : 861 -877.

    • Search Google Scholar
  • WHO (2008): European Health for All Database (HFA-DB). http://www.euro.who.int/en/what-we-do/data-and-evidence/databases/european-health-for-all-database-hfa-db2

  • Wimo, A. — Jönsson, L. — Gustavsson, A. — McDaid, D. — Ersek, K. — Georges, J. — Gulácsi, L. — Karpati, K. — Kenigsberg, P. — Valtonen, H. (2010): The Economic Impact of Dementia in Europe in 2008 — Cost Estimates from the Eurocode Project. International Journal of Geriatric Psychiatry, forthcoming.